These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27783867)

  • 1. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
    Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
    Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
    Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
    Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
    Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
    J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
    Keshava S; Rao LV; Pendurthi UR
    Sci Rep; 2016 Nov; 6():36829. PubMed ID: 27833109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
    Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
    Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy using adenovirus against malignant mesothelioma.
    Gotoh A; Kanno T; Nagaya H; Nakano T; Tabata C; Fukuoka K; Tagawa M; Nishizaki T
    Anticancer Res; 2012 Sep; 32(9):3743-7. PubMed ID: 22993314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
    Adusumilli PS; Stiles BM; Chan MK; Mullerad M; Eisenberg DP; Ben-Porat L; Huq R; Rusch VW; Fong Y
    J Gene Med; 2006 May; 8(5):603-15. PubMed ID: 16475242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.
    Takayama K; Reynolds PN; Adachi Y; Kaliberova L; Uchino J; Nakanishi Y; Curiel DT
    Cancer Gene Ther; 2007 Jan; 14(1):105-16. PubMed ID: 17024232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.
    Kubo S; Kawasaki Y; Yamaoka N; Tagawa M; Kasahara N; Terada N; Okamura H
    J Gene Med; 2010 Aug; 12(8):681-92. PubMed ID: 20635326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
    Kelly KJ; Woo Y; Brader P; Yu Z; Riedl C; Lin SF; Chen N; Yu YA; Rusch VW; Szalay AA; Fong Y
    Hum Gene Ther; 2008 Aug; 19(8):774-82. PubMed ID: 18754710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
    Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
    Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
    Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
    Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.